Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE-PE study of perioperative pembrolizumab in resectable kidney cancer metastases
2022-001077-30Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Consorzio Oncotech. Primary endpoint: Relapse-free survival. Started Sep 2022; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2022-001077-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001077-30.